» Articles » PMID: 35102251

The Ubiquitin E3 Ligase ARIH1 Regulates HnRNP E1 Protein Stability, EMT and Breast Cancer Progression

Overview
Journal Oncogene
Date 2022 Feb 1
PMID 35102251
Authors
Affiliations
Soon will be listed here.
Abstract

The epithelial to mesenchymal transition (EMT), a process that is aberrantly activated in cancer and facilitates metastasis to distant organs, requires coordinated transcriptional and post-transcriptional control of gene expression. The tumor-suppressive RNA binding protein, hnRNP-E1, regulates splicing and translation of EMT-associated transcripts and it is thought that it plays a major role in the control of epithelial cell plasticity during cancer progression. We have utilized yeast 2 hybrid screening to identify novel hnRNP-E1 interactors that play a role in regulating hnRNP-E1; this approach led to the identification of the E3 ubiquitin ligase ARIH1. Here, we demonstrate that hnRNP-E1 protein stability is increased upon ARIH1 silencing, whereas, overexpression of ARIH1 leads to a reduction in hnRNP-E1. Reduced ubiquitination of hnRNP-E1 detected in ARIH1 knockdown (KD) cells compared to control suggests a role for ARIH1 in hnRNP-E1 degradation. The identification of hnRNP-E1 as a candidate substrate of ARIH1 led to the characterization of a novel function for this ubiquitin ligase in EMT induction and cancer progression. We demonstrate a delayed induction of EMT and reduced invasion in mammary epithelial cells silenced for ARIH1. Conversely, ARIH1 overexpression promoted EMT induction and invasion. ARIH1 silencing in breast cancer cells significantly attenuated cancer cell stemness in vitro and tumor formation in vivo. Finally, we utilized miniTurboID proximity labeling to identify novel ARIH1 interactors that may contribute to ARIH1's function in EMT induction and cancer progression.

Citing Articles

ARIH1 Inhibition Promotes Microtubule Stability and Sensitizes Breast Cancer Cells to Microtubule-Stabilizing Agents.

Elshaer M, Howley B, Howe P Cancers (Basel). 2025; 17(5).

PMID: 40075632 PMC: 11898827. DOI: 10.3390/cancers17050782.


Ubiquitination Enzymes in Cancer, Cancer Immune Evasion, and Potential Therapeutic Opportunities.

Awan A, Osman M, Khan O Cells. 2025; 14(2).

PMID: 39851497 PMC: 11763706. DOI: 10.3390/cells14020069.


The Clinical Prediction Value of the Ubiquitination Model Reflecting the Microenvironment Infiltration and Drug Sensitivity in Breast Cancer.

Ma H, Cao J, Zhang Y, Yang J, Wang X, Yu Y J Cancer. 2025; 16(3):784-801.

PMID: 39781342 PMC: 11705054. DOI: 10.7150/jca.101525.


Ubiquitination regulates autophagy in cancer: simple modifications, promising targets.

Wu Y, Chen Y, Tian X, Shao G, Lin Q, Sun A J Transl Med. 2024; 22(1):985.

PMID: 39482684 PMC: 11526641. DOI: 10.1186/s12967-024-05565-1.


NUP37 accumulation mediated by TRIM28 enhances lipid synthesis to accelerate HCC progression.

Liu Z, Hu Q, Luo Q, Zhang G, Yang W, Cao K Oncogene. 2024; 43(44):3255-3267.

PMID: 39294431 DOI: 10.1038/s41388-024-03167-1.


References
1.
Blobe G, Schiemann W, Lodish H . Role of transforming growth factor beta in human disease. N Engl J Med. 2000; 342(18):1350-8. DOI: 10.1056/NEJM200005043421807. View

2.
Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

3.
Radisky D . Epithelial-mesenchymal transition. J Cell Sci. 2005; 118(Pt 19):4325-6. DOI: 10.1242/jcs.02552. View

4.
Howley B, Howe P . TGF-beta signaling in cancer: post-transcriptional regulation of EMT via hnRNP E1. Cytokine. 2018; 118:19-26. PMC: 6063801. DOI: 10.1016/j.cyto.2017.12.032. View

5.
Chaudhury A, Hussey G, Ray P, Jin G, Fox P, Howe P . TGF-beta-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI. Nat Cell Biol. 2010; 12(3):286-93. PMC: 2830561. DOI: 10.1038/ncb2029. View